title: A safety study of high concentration and high frequency intravitreal injection of conbercept in rabbits.
abstract: The novel anti-VEGF drug conbercept has been used in the treatment of several retinal neovascular diseases. Owning to the alteration of the structure, the newest drug is capable of combining more molecular targets and present higher affinity to the angiogenesis promoting factors. However, it is unknown whether it will cause any unwanted effects like other anti-VEGF agents. We studied the short-term safety of high concentration and high frequency intravitreal injection of conbercept in rabbits. Intraocular pressure, fundus-photography, ERGs were applied. Retinal morphology, the amount of apoptotic cells and protein levels of IL-6, IL-8 and TNF-α in the aqueous humor were determined. Retinal proteomics was detected using tandem mass tags (TMTs) quantitative mass spectrometry. The difference of IOP, ERGs, protein levels of inflammatory factors among rabbits received conbercept and PBS was not significant (P > 0.05). Fundus photographs and retinal morphology of animals in the conbercept-injected groups mimic those observed in the PBS-injected groups. No TUNEL-positive cell was seen in the retinal ganglion cell layer in the conbercept-injected groups. Proteomics did not show significant changes of inflammation or apoptosis associated proteins in the conbercept-injected eyes. We conclude that intravitreal injection of high concentration and high frequency conbercept is well tolerated at least in a short-term in rabbits.
authors.affiliation: Department of Ophthalmology, the First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology, Chongqing Eye Institute, Chongqing, China.|Shenzhen Eye Hospital, Affiliated Shenzhen Eye Hospital of Jinan University, Shenzhen Key Laboratory of Ophthalmology, Shenzhen, China.
authors.forename: Jiaming
authors.initials: J
authors.lastname: Wang
authors.affiliation: Department of Ophthalmology, the First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology, Chongqing Eye Institute, Chongqing, China.
authors.forename: Chunyan
authors.initials: C
authors.lastname: Lei
authors.affiliation: Department of Ophthalmology, the First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology, Chongqing Eye Institute, Chongqing, China.
authors.forename: Lifei
authors.initials: L
authors.lastname: Tao
authors.affiliation: Chengdu Kanghong Biotechnology Co. Ltd, Chengdu, China.
authors.forename: Quan
authors.initials: Q
authors.lastname: Wu
authors.affiliation: Chengdu Kanghong Biotechnology Co. Ltd, Chengdu, China.
authors.forename: Xiao
authors.initials: X
authors.lastname: Ke
authors.affiliation: Department of Ophthalmology, the First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology, Chongqing Eye Institute, Chongqing, China.
authors.forename: Yiguo
authors.initials: Y
authors.lastname: Qiu
authors.affiliation: People's Hospital of Zhengzhou University, Henan Eye Institute, Henan Eye Hospital, Henan Provincial People's Hospital, Zhengzhou, China. bolei99@126.com.
authors.forename: Bo
authors.initials: B
authors.lastname: Lei
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects*; D000818:Animals; D015415:Biomarkers; D004596:Electroretinography; D004797:Enzyme-Linked Immunosorbent Assay; D005451:Fluorescein Angiography; D007150:Immunohistochemistry; D007429:Intraocular Pressure / Q000187:drug effects; D058449:Intravitreal Injections; D020543:Proteome; D040901:Proteomics / Q000379:methods; D011817:Rabbits; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage* / Q000009:adverse effects*; D012160:Retina / Q000187:drug effects / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D015415:Biomarkers; D020543:Proteome; D011993:Recombinant Fusion Proteins; C527363:KH902 fusion protein